1. Market Research
  2. > Cardiometabolic Disease - Pipeline Review, H2 2013

Cardiometabolic Disease - Pipeline Review, H2 2013

  • July 2013
  • -
  • Global Markets Direct
  • -
  • 31 pages

Cardiometabolic Disease - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Cardiometabolic Disease - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Cardiometabolic Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cardiometabolic Disease. Cardiometabolic Disease - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Cardiometabolic Disease.
- A review of the Cardiometabolic Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Cardiometabolic Disease pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Cardiometabolic Disease.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Cardiometabolic Disease pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Cardiometabolic Disease - Pipeline Review, H2 2013
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Cardiometabolic Disease Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Cardiometabolic Disease 7
Cardiometabolic Disease Therapeutics under Development by Companies 9
Mid Clinical Stage Products 10
Comparative Analysis 10
Discovery and Pre-Clinical Stage Products 11
Comparative Analysis 11
Cardiometabolic Disease Therapeutics - Products under Development by Companies 12
Companies Involved in Cardiometabolic Disease Therapeutics Development 13
Torrent Pharmaceuticals Limited 13
Zafgen Inc. 14
miRagen Therapeutics, Inc. 15
Cardiometabolic Disease - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Drug Profiles 21
TRC-150094 - Drug Profile 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
Cardiometabolic Disease Program - Drug Profile 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
MGN-5804 - Drug Profile 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
DS-102 - Drug Profile 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
DS-103 - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
messenger RNA Therapeutics Program - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
Cardiometabolic Disease Therapeutics - Discontinued Products 28
Cardiometabolic Disease Therapeutics - Dormant Products 29
Appendix 30
Methodology 30
Coverage 30
Secondary Research 30
Primary Research 30
Expert Panel Validation 30
Contact Us 31
Disclaimer 31

List of Tables

Number of Products Under Development for Cardiometabolic Disease, H2 2013 7
Products under Development for Cardiometabolic Disease - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Comparative Analysis by Mid Clinical Stage Development, H2 2013 10
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 11
Products under Development by Companies, H2 2013 12
Torrent Pharmaceuticals Limited, H2 2013 13
Zafgen Inc., H2 2013 14
miRagen Therapeutics, Inc., H2 2013 15
Assessment by Monotherapy Products, H2 2013 16
Assessment by Stage and Route of Administration, H2 2013 18
Assessment by Stage and Molecule Type, H2 2013 20
Cardiometabolic Disease Therapeutics - Discontinued Products 28
Cardiometabolic Disease Therapeutics - Dormant Products 29

List of Figures

Number of Products under Development for Cardiometabolic Disease, H2 2013 7
Products under Development for Cardiometabolic Disease - Comparative Analysis, H2 2013 8
Products under Development by Companies, H2 2013 9
Mid Clinical Stage Products, H2 2013 10
Discovery and Pre-Clinical Stage Products, H2 2013 11
Assessment by Monotherapy Products, H2 2013 16
Assessment by Route of Administration, H2 2013 17
Assessment by Stage and Route of Administration, H2 2013 18
Assessment by Molecule Type, H2 2013 19
Assessment by Stage and Molecule Type, H2 2013 20

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.